Balaji Gandhi Sells 8,045 Shares of Phreesia, Inc. (NYSE:PHR) Stock

Phreesia, Inc. (NYSE:PHR) CFO Balaji Gandhi sold 8,045 shares of the stock in a transaction dated Tuesday, April 8th. The stock was sold at an average price of $23.85, for a total transaction of $191,873.25. Following the transaction, the chief financial officer now owns 108,411 shares in the company, valued at approximately $2,585,602.35. The trade was a 6.91 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Balaji Gandhi also recently made the following trade(s):

• On Wednesday, March 26th, Balaji Gandhi sold 1,827 shares of Phreesia stock. The shares were sold at an average price of $27.46, for a total transaction of $50,169.42.
• On Tuesday, February 18th, Balaji Gandhi sold 5,771 shares of Phreesia stock. The stock was sold at an average price of $30.04, for a total transaction of $173,360.84.
• On Thursday, February 13th, Balaji Gandhi sold 28,759 shares of Phreesia stock. The shares were sold at an average price of $30.00, for a total value of $862,770.00.
• On Monday, January 27th, Balaji Gandhi sold 4,813 shares of Phreesia stock. The stock was sold at an average price of $27.48, for a total value of $132,261.24.
• On Tuesday, January 21st, Balaji Gandhi sold 5,827 shares of Phreesia stock. The shares were sold at an average price of $27.31, for a total value of $159,135.37.
• On Wednesday, January 15th, Balaji Gandhi sold 836 shares of Phreesia stock. The shares were sold at an average price of $26.98, for a total transaction of $22,555.28.

Phreesia Stock Performance

Shares of Phreesia stock traded down $1.11 during trading on Thursday, hitting $24.09. 639,829 shares of the company’s stock were exchanged, compared to its average volume of 434,457. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -16.39 and a beta of 0.82. The business has a 50-day simple moving average of $26.66 and a 200-day simple moving average of $24.25. Phreesia, Inc. has a 52-week low of $17.07 and a 52-week high of $30.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 1.74 and a current ratio of 1.74.

Hedge Funds Weigh In On Phreesia

A number of institutional investors have recently modified their holdings of PHR. Zacks Investment Management acquired a new stake in Phreesia during the third quarter worth about $631,000. State Street Corp grew its stake in shares of Phreesia by 7.1% during the 3rd quarter. State Street Corp now owns 1,327,586 shares of the company’s stock worth $30,256,000 after purchasing an additional 88,517 shares during the period. Charles Schwab Investment Management Inc. grew its stake in shares of Phreesia by 10.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 493,448 shares of the company’s stock worth $12,415,000 after purchasing an additional 46,209 shares during the period. Wesbanco Bank Inc. increased its holdings in shares of Phreesia by 76.9% during the 4th quarter. Wesbanco Bank Inc. now owns 46,000 shares of the company’s stock valued at $1,157,000 after purchasing an additional 20,000 shares in the last quarter. Finally, Barclays PLC lifted its stake in shares of Phreesia by 83.6% in the 3rd quarter. Barclays PLC now owns 94,929 shares of the company’s stock valued at $2,163,000 after purchasing an additional 43,225 shares during the period. Hedge funds and other institutional investors own 92.10% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently commented on the stock. KeyCorp increased their target price on shares of Phreesia from $28.00 to $30.00 and gave the company an “overweight” rating in a research report on Wednesday, January 8th. Robert W. Baird decreased their price objective on Phreesia from $34.00 to $30.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Royal Bank of Canada upgraded Phreesia from a “sector perform” rating to an “outperform” rating and boosted their target price for the stock from $24.00 to $32.00 in a research note on Wednesday, January 8th. Truist Financial increased their price target on Phreesia from $31.00 to $34.00 and gave the company a “buy” rating in a research note on Wednesday, December 11th. Finally, Piper Sandler reissued an “overweight” rating and issued a $33.00 price target (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. Twelve equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock presently has an average rating of “Buy” and a consensus target price of $31.33.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.